Pasithea Therapeutics Snubs Takeover Bid, OKs $4M Share Buyback Plan
- July 20th, 2023
- 419 views
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has authorized a $4.0 million share repurchase plan (through a tender offer), to buy approximately 5.7 million shares of its outstanding common stock at $0.70 per share.
The company's executive officers and directors won't tender any shares in the offer. If oversubscribed, the repurchase will be done on a pro rata basis.
In addition, Pasithea confirmed the rejection of an unsolicited proposal from Lucy Scientific Discovery, Inc. (Nasdaq: LSDI) to acquire all outstanding shares of Pasithea common stock for $0.60 in cash plus $0.25 worth of Lucy common stock.
Following a comprehensive review with independent advisors, Pasithea's Special Committee deemed the proposal inadequate, stating it doesn't reflect the company's strategic value and growth prospects.
$KTTA was trading at $0.58 in pre-market, up $0.11 (+22.21%) after the announcements.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login